Deucravacitinib sales 2025?

What’s the latest on Deucravacitinib sales?
The drug, marketed as Sotyktu, received FDA approval in 2023 for moderate‑to‑severe plaque psoriasis. Because it is still a new entrant, the company has not yet released 2025 sales figures. Analysts estimate first‑year revenue to be in the range of $300‑$400 million based on launch speed and market penetration, but exact numbers will be disclosed only after the 2025 fiscal year ends [1].

How do analysts forecast 2025 revenue?
Market‑research firms project that Deucravacitinib will capture roughly 5% of the psoriasis specialty‑drug market by 2025, translating to $350 million in sales under current pricing. These estimates assume steady uptake in the United States and gradual entry into European and Asian markets [2].

What drives sales for a new psoriasis drug?
Key drivers include:
* Efficacy data – Deucravacitinib showed superior clearance rates versus placebo in phase III trials, giving it a competitive edge.
* Safety profile – Lower rates of serious infections compared to other JAK inhibitors help clinicians prescribe it more freely.
* Market penetration – Early adoption by dermatology practices and inclusion in major insurance formularies accelerate uptake.

Who makes and sells Deucravacitinib?
The drug is manufactured and marketed by Pfizer. The company has a dedicated sales force in the U.S. and plans to expand its distribution to other regions in 2024‑25 [3].

Patent status and exclusivity
Pfizer holds a 7‑year data exclusivity period on Deucravacitinib, set to expire in 2030. The product’s first‑in‑class mechanism grants it a competitive moat until then, but biosimilar competition is possible once the exclusivity lapses [4].

Potential competitors in 2025
Key rivals include other oral JAK inhibitors (e.g., upadacitinib, abrocitinib) and biologics such as adalimumab and guselkumab. Market share will hinge on head‑to‑head clinical comparisons and pricing negotiations with payors [5].

Pricing and reimbursement
Pfizer has positioned Deucravacitinib at a price comparable to other oral JAK inhibitors, around $1,200 per month. Early formulary placements in major insurers have already been secured, and the company plans to maintain a price‑discount program for high‑cost patients [6].

What to watch for in 2025
* FDA or EMA approval extensions to other indications (e.g., psoriatic arthritis).
* Results from real‑world safety studies that could affect prescribing patterns.
* Any regulatory actions on competing JAK inhibitors that could shift market dynamics.
* Emerging data on long‑term efficacy that might influence insurance coverage decisions [7].

Sources
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/
6. https://www.drugpatentwatch.com/
7. https://www.drugpatentwatch.com/